Despite the FDA’s CNPV scheme generating high interest, the process around how voucher awards are prioritised remains unclear ...
By Sneha S K Feb 13 (Reuters) - Disc Medicine said on Friday the U.S. Food and Drug Administration declined to approve its drug to treat a rare genetic disorder. The drug, bitopertin, was being ...
The decision follows a pattern of policy shifts, including the rollback of COVID-19 recommendations and cancellation of mRNA funding.